These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 8683305

  • 1. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
    Kwekkeboom DJ, Lamberts SW, Habbema JD, Krenning EP.
    J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
    [Abstract] [Full Text] [Related]

  • 2. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging.
    Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, McIlrath EM.
    QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953
    [Abstract] [Full Text] [Related]

  • 3. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
    Mateos Fernández J, Pons Pons F, Fuster Pelfort D, Vidal-Sicart S, Lomeña Caballero F, Herranz García-Romero R.
    Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
    [Abstract] [Full Text] [Related]

  • 4. Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis.
    Dimitroulopoulos D, Xynopoulos D, Tsamakidis K, Paraskevas E, Zisimopoulos A, Andriotis E, Fotopoulou E, Kontis M, Paraskevas I.
    World J Gastroenterol; 2004 Dec 15; 10(24):3628-33. PubMed ID: 15534919
    [Abstract] [Full Text] [Related]

  • 5. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
    Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli JP, Parmentier C.
    J Nucl Med; 1996 Jun 15; 37(6):912-6. PubMed ID: 8683310
    [Abstract] [Full Text] [Related]

  • 6. [The scintigraphy of somatostatin receptors in the carcinoid tumor].
    Banzo J, Abós MD, Prats E, Delgado M, Razola P, García S, Gomollón F, García F.
    Rev Esp Med Nucl; 2001 Feb 15; 20(1):11-8. PubMed ID: 11181324
    [Abstract] [Full Text] [Related]

  • 7. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
    Wiedenmann B, Bäder HM, Scherubl H, Fett U, Zimmer T, Hamm B, Koppenhagen K, Riecken EO.
    Semin Oncol; 1994 Oct 15; 21(5 Suppl 13):29-32. PubMed ID: 7992077
    [No Abstract] [Full Text] [Related]

  • 8. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome.
    Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, Reubi JC, Lamberts SW.
    Digestion; 1994 Oct 15; 55 Suppl 3():54-9. PubMed ID: 7698538
    [Abstract] [Full Text] [Related]

  • 9. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG, Farahati J, Bier D, Knust EJ, Reiners C.
    Nuklearmedizin; 1995 Feb 15; 34(1):1-7. PubMed ID: 7724358
    [Abstract] [Full Text] [Related]

  • 10. Somatostatin receptor imaging.
    Kwekkeboom DJ, Krenning EP.
    Semin Nucl Med; 2002 Apr 15; 32(2):84-91. PubMed ID: 11965603
    [Abstract] [Full Text] [Related]

  • 11. Somatostatin receptor imaging for neuroendocrine tumors.
    de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP.
    Pituitary; 2006 Apr 15; 9(3):243-8. PubMed ID: 17001462
    [Abstract] [Full Text] [Related]

  • 12. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
    Gotthardt M, Béhé MP, Grass J, Bauhofer A, Rinke A, Schipper ML, Kalinowski M, Arnold R, Oyen WJ, Behr TM.
    Endocr Relat Cancer; 2006 Dec 15; 13(4):1203-11. PubMed ID: 17158765
    [Abstract] [Full Text] [Related]

  • 13. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ, Dehdashti F, Cutler PD, Schwarz SW, Laforest R, Bass LA, Lewis JS, McCarthy DW.
    J Nucl Med; 2001 Feb 15; 42(2):213-21. PubMed ID: 11216519
    [Abstract] [Full Text] [Related]

  • 14. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N, Furno A, Sforza A, Chiarini V, Graziano E, Zampa G, Turba E.
    Q J Nucl Med; 1995 Dec 15; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [Abstract] [Full Text] [Related]

  • 15. Factor analysis of dynamic series (FADS) in somatostatin receptor imaging.
    Kolesnikov-Gauthier H, Huglo D, Nocaudie M, Marchandise X.
    J Nucl Med; 1999 Jan 15; 40(1):33-9. PubMed ID: 9935053
    [Abstract] [Full Text] [Related]

  • 16. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
    Modlin IM, Cornelius E, Lawton GP.
    Arch Surg; 1995 Apr 15; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
    [Abstract] [Full Text] [Related]

  • 17. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
    Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB.
    J Clin Endocrinol Metab; 2001 Feb 15; 86(2):895-902. PubMed ID: 11158063
    [Abstract] [Full Text] [Related]

  • 18. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide.
    Wangberg B, Forssell-Aronsson E, Tisell LE, Nilsson O, Fjalling M, Ahlman H.
    Br J Cancer; 1996 Mar 15; 73(6):770-5. PubMed ID: 8611378
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.